Drug-eluting balloon catheters for lower limb peripheral arterial disease: the evidence to date.
| Autor: | Barkat, Mohamed, Torella, Francesco, Antoniou, George A. |
|---|---|
| Předmět: |
ARTERIAL disease treatment
LEG blood-vessels DRUG-eluting stents TRANSLUMINAL angioplasty REVASCULARIZATION (Surgery) SALVAGE therapy DISEASES PERIPHERAL vascular disease treatment BIOMEDICAL materials BLOOD vessels CARDIOVASCULAR agents FEMORAL artery LEG VASCULAR resistance MEDICAL equipment PERIPHERAL vascular diseases SYSTEMATIC reviews TREATMENT effectiveness POPLITEAL artery EQUIPMENT & supplies |
| Zdroj: | Vascular Health & Risk Management; May2016, Vol. 12, p199-208, 10p |
| Abstrakt: | A significant proportion of patients with severe lower limb peripheral arterial disease require revascularization. Over the past decade, an endovascular-first approach even for complex disease has gained widespread use among vascular specialists. An important limitation of percutaneous transluminal balloon angioplasty or stenting remains the occurrence of restenosis. Drug-coated balloons have emerged as an exciting technology developed to overcome the limitations of standard balloon angioplasty and stenting. Drug-eluting devices inhibit neointimal growth of vascular smooth muscle cells with the potential of preventing restenosis. This review provides a synopsis of the up-to-date evidence on the role of drug-coated balloons in the treatment of lower limb peripheral arterial disease. Bibliographic searches were conducted using MEDLINE, EMBASE, and the Cochrane Library electronic database. Eleven randomized clinical trials, two systematic reviews, and a published registry providing the best available evidence were identified. Current evidence suggests that angioplasty with drug-coated balloon is reliable, safe, and efficient in increasing patency rates and reducing target lesion revascularization and restenosis. However, it remains unknown whether these improved results can translate into beneficial clinical outcomes, as current randomized clinical trials have failed to demonstrate a significant benefit in limb salvage and mortality. Further randomized trials focusing on clinical and functional outcomes of drug-eluting balloons and on cost versus clinical benefit are required. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|